Pharma BD Deal Intelligence
Total loss: foliglurax failed its Phase II endpoint in 2020 and Lundbeck wrote off the entire ~EUR 100M asset value
Full analysis, sources & comparables →Lundbeck is paying €100M ($123M) up front for Prexton's mid-phase Parkinson's candidate, with up to €805M in milestones. Mid-sized players would have preferred…
Foliglurax's failure in the AMBLED Phase 2 study marks the third major setback in Lundbeck's recent acquisition strategy, with the company writing down the…
Final published Phase 2 AMBLED data confirmed foliglurax failed to reduce OFF-time or dyskinesia versus placebo; Lundbeck discontinued development of the…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Lundbeck announced March 2018 acquisition of Swiss biotech Prexton Therapeutics for EUR 100M (~$123M) upfront plus up to EUR 805M (~$992M) in clinical, regulatory and commercial milestones (total up to ~$1.1B). Adds foliglurax, a Phase 2 mGluR4 positive allosteric modulator targeting OFF-time reduction and L-DOPA-induced dyskinesia in Parkinson's disease.
Total loss: foliglurax failed its Phase II endpoint in 2020 and Lundbeck wrote off the entire ~EUR 100M asset value
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| H. Lundbeck A/S / Prexton Therapeutics BV (this deal) | 2018 | $1.1B | 14 |
| H. Lundbeck A/S / Alder BioPharmaceuticals, Inc. | 2019 | $1.9B | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
| Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical | 1995 | — | 82 |
← Browse all deals · How we score deals
More: 2018 deals · Neurology deals